Travere Therapeutics (TVTX) Acquisitions (2014 - 2016)

Travere Therapeutics has reported Acquisitions for 3 years, with the latest figure at $115000.0 in Q4 2016.

• For the quarter ending Q4 2016, Acquisitions changed N/A year-over-year to $115000.0; the trailing twelve-month figure through Dec 2017 stood at $115000.0 (down 81.3% YoY), and the FY2020 full-year result was $95.3 million, changed N/A from the prior year.
• Acquisitions for Q4 2016 stood at $115000.0, down from $500000.0 in the prior quarter.
• The five-year high for Acquisitions was $33.4 million in Q1 2015, with the low at $115000.0 in Q4 2016.
• Historically, Acquisitions has averaged $15.8 million across 3 years, with a median of $14.8 million in 2014.
• The largest YoY upside for Acquisitions was 14.68% in 2015 against a maximum downside of 14.68% in 2015.
• Travere Therapeutics' Acquisitions stood at $29.2 million in 2014, then gained by 14.68% to $33.4 million in 2015, then sank by 99.66% to $115000.0 in 2016.
• The last three Acquisitions figures came in at $115000.0 (Q4 2016), $500000.0 (Q2 2016), and $33.4 million (Q1 2015), per Business Quant data.